Welcome to Labeled Immunoassays and Clinical Medicine website!

Clinical Observation of 89Srcl2 Therapy in Patients with Bone Metastases

Expand
  • Department of Nuclear Medicine, Chengdu Fifth People’s Hospital, Chengdu 611130, China

Received date: 2014-03-14

  Revised date: 2014-08-18

  Online published: 2014-11-06

Abstract

Objective To investigate the therapeutic effects of strontium-89 therapy in patients with bone metastases. Methods Seventy-five cancer patients with multiple bone metastases confirmed with whole body bone scan imaging were treated with strontium-89. The catabolic effects of bone pain, the changes of peripheral hemogram and bone metastases lesions were analyzed before and after strontium-89 therapy. Results Among seventy-five cases of patients, sixty cases appeared different degree of pain relief, and the remission rate was 80% (P<0.01); Nineteen patients pain disappeared completely. There was no significant change for peripheral hemogram during treatment period and the bone metastases remission rate in all cancer patients was 89% (P<0.01). Conclusion Strontium-89 therapy is an effective therapeutic method for patients with bone metastases with favorable effects on relieving pain, low reaction of toxicity and high remission rate.

Cite this article

HU De-Sheng, SHI Lei . Clinical Observation of 89Srcl2 Therapy in Patients with Bone Metastases[J]. Labeled Immunoassays and Clinical Medicine, 2014 , 21(5) : 540 . DOI: 10.11748/bjmy.issn.1006-1703.2014.05.014

Outlines

/